Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | MGAM | O43451 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214470 | 0.91 | KDM4E (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30607045 | 0.90 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL28562307 | 0.90 | KDM4E (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL28017777 | 0.90 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2216529 | 0.90 | KDM4E (0.67) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL23859789 | 0.90 | KDM4E (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL16489364 | 0.90 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL28373648 | 0.89 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL15426098 | 0.89 | KMT2A (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL23859787 | 0.89 | KDM4E (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-10857136-B2 | Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis | SJT MOLECULAR RESEARCH, SL (ES) | 2020-12-08 | — | — | US | disclosed |
| CN-109575020-A | Beta-carboline derivatives and preparation method thereof and application in preparation of anti-tumor drugs | 河北大学 | 2019-04-05 | — | — | CN | disclosed |
| EP-2691394-B1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2017-05-10 | — | — | EP | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| WO-2012130912-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2012-10-04 | — | — | WO | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | HDAC1 796/4885HDAC2 859/4885HDAC3 574/4885 |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | HDAC1 796/4885HDAC2 859/4885HDAC3 574/4885 |
| US-10857136-B2 | Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis | FABP1, LIPC, SLC10A1 | HDAC1 839/4885HDAC2 1084/4885HDAC3 572/4885 |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | HDAC1 3027/4885HDAC2 1795/4885HDAC3 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.